Restoring the function of joint surfaces using tissueengineering
The first THA (total hip arthroplasty) performed in younger patients will constitute 52%
The first TKA (total knee arthroplasty) 55%
Is a disease characterized by joint pain and dysfunction caused by the progressive and irreversible loss of joint cartilage.
At an advanced stage of the disease, it becomes necessary touseanendoprosthesis.Removal of the joint means its permanent destruction and the final loss of periarticular bone tissue.
In the case of disease progression and periimplant tissue degeneration,the next stage is an even more extensive excision of the tissues and theimplantation
of larger implant – which usually ends with a permanent disabilityafter revision surgeries.
130 million patients will be suffering
from osteoarthritis
40 million will be disabled
It is significant that the disease affects younger and younger patients, analyzing data so far
Value of the global endoprosthesis market:
2019 - USD 19.32 billion
2027 - USD 29.79 billion
5.6% CAGR
Global cartilage reconstruction market value:
2022 - USD 984,25 mln
2030 - USD 3 095,64 mln
15,4% CAGR
Worldwide, 9.6% of men and 18% of women over the age of 60 have symptoms of osteoarthritis.
80% of them suffer from limited movement and 25% areunable to perform basic life activities.
The prosthesis does not rebuild into tissue. Its implantation destroys bone and cartilage irreversibly.
Progressive tissue lysis around the endoprosthesis.
Inability to fill and restore the tissue after loosening the implant.
In the case of peri-prosthetic fractures, it is necessary to replace with extensive damage to the bones and surrounding tissues.
Endoprosthesis loosening - revisions of endoprostheses lead to the loss of bone tissue and surrounding structures, which results in permanent disability.
Inability to reproduce the full range of motion. Inability to return to full fitness.
Hip prosthesis - risk of dislocation, Hip and knee prosthesis - complex periprosthetic bone fractures.
Age and health restrictions.
Significant risk of infection (not only perisurgical).
The need for revision surgery that appears along with the implantation of an endoprosthesis in younger age groups 45-55 (1- 3 per patient) - increased risk of complications.
Lack of technology to restore full-thick and stable hyaline cartilage.
Limited effectiveness compared to traditional methods (endoprothesis).
Possibility to treat small cartilage defects.
Unknown effectiveness in people over 55 years of age.
High cost of therapy.
In the United States, only 0.4% of all surgically treated patients undergo regenerative treatment , but this group is gradually growing.
Starodworska 1
80-180 Gdansk, Poland
arthec@arthec.eu
ARTHEC Spółka Akcyjna
ul. Starodworska 1, 80-137 Gdańsk
NIP: 583-336-71-06
KRS: 0001103084
Kapitał zakładowy: 100.000 PLN